
    
      The study is designed in three parts, A, B and C

      Part A: single-center, double-blind, randomized, placebo-controlled, single ascending dose

      Part B: single-center, double-blind, randomized, placebo-controlled, multiple ascending dose

      Part C: single-center, open-label, single dose in CYP2C9 poor metabolizers
    
  